1910 Genetics Ventures

www.1910.ai

VCMatch tracks 1910 Genetics Ventures as an investor focused on AI/ML, Biotech, and Pharma companies, Seed and Series A rounds, and United States, Boston, Ma, and Global markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A

Focus Areas

AI/ML, Biotech, Pharma

Geography

United States, Boston, MA, and Global

Investment Thesis

The firm’s thesis centers on challenging the status quo in drug discovery by deploying AI/ML, massive multimodal data, and integrated wet-lab automation to reverse declining pharmaceutical R&D productivity. They believe platform-level solutions that solve data scarcity, model training, compute, and wet-lab validation together will accelerate delivery of better drugs faster, and therefore prioritize building an end-to-end technology stack (ITO™) and partnering models to embed that stack into biopharma organizations.

Is 1910 Genetics Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

1910 Genetics Ventures is most relevant for founders raising Seed and Series A rounds in AI/ML, Biotech, Pharma, and Medtech, especially across United States, Boston, MA, and Global.

Focus statement

They focus on AI-driven molecular design & optimization and AI-driven precision target identification across small and large molecules, leveraging federated learning, multiomic patient-derived data, and high-throughput proxy assays to enable pre-competitive collaboration with pharma and biotech partners.

Value Add

End-to-end ITO™ platform that integrates "massive multimodal data, frontier AI models, and high-throughput lab automation" (data → models → wet lab closed-loop).
Federated learning / pre-competitive consortium capability: "Private data never leaves the local devices or Partners' data centers" enabling partners to collaboratively train a Global Model without sharing raw data.
Ultra-high-throughput surrogate ("proxy") assays that "can generate up to 100,000,000,000 data points in one week," addressing data sparsity that limits AI in drug discovery.
Model Foundry™: "Our SOTA Model Foundry™ consists of 100’s of AI/ML models and a Multi-AI Agent System" for multi-parameter optimization and molecule provenance/ safety features.
Robotics-driven lab and use of wet-lab ground truth: they "leverage wet lab ground truth data – biopharma's gold standard" and a "SOTA robotics-driven lab facility" to validate AI-designed molecules.
Cloud and compute partnerships (Microsoft Azure Quantum Elements, NVIDIA) and demonstrated investor support from leading tech/bio backers ("Microsoft’s Venture Fund, Accenture, FoundersX Ventures, Playground Global, OpenAI’s Sam Altman, Y Combinator").
Flexible commercial/partnering models (Horizontal ITO™ Infrastructure, Co-Engineering, Co-Discovery, PaaS, Asset Licensing, Data Licensing) enabling multiple routes to capture value.